SK Biopharmaceuticals Co Ltd
KRX:326030
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
75 700
125 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
Income from Continuing Operations
SK Biopharmaceuticals Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
-₩35.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩162.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
30%
|
CAGR 10-Years
5%
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Income from Continuing Operations
₩103.3B
|
CAGR 3-Years
24%
|
CAGR 5-Years
44%
|
CAGR 10-Years
16%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩207.2B
|
CAGR 3-Years
87%
|
CAGR 5-Years
35%
|
CAGR 10-Years
15%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
₩10.8B
|
CAGR 3-Years
167%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-1%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Income from Continuing Operations
₩16.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
81%
|
CAGR 10-Years
16%
|
|
SK Biopharmaceuticals Co Ltd
Glance View
SK Biopharmaceuticals Co Ltd., a prominent player in the global biopharmaceutical landscape, has carved out a niche in the development of innovative therapies for central nervous system (CNS) disorders. Founded in South Korea as a subsidiary of the SK Group, the company has swiftly gained recognition for its commitment to research and development, particularly in the realm of epilepsy treatments. Its flagship product, Cenobamate, has received approvals in various international markets, establishing a substantial revenue stream and bolstering SK Biopharmaceuticals’ reputation for tackling complex neurological conditions. This focus on underserved medical needs not only highlights the company’s scientific prowess but also reflects its strategic positioning within a growing market projected to expand significantly in the coming years. For investors, SK Biopharmaceuticals embodies a blend of growth potential and stability, driven by a robust pipeline of both established and novel therapies. The company is leveraging cutting-edge technology and extensive clinical research to explore additional indications for its existing products while continuing to develop new candidates. With a strong financial foundation and increasing market penetration, SK Biopharmaceuticals is poised to capitalize on the surging demand for innovative CNS treatments. As the company continues to expand its footprint globally, its commitment to quality, patient-centric approaches, and strategic partnerships will likely enhance shareholder value, making it an attractive consideration for those looking to invest in the biopharmaceutical sector.
See Also
What is SK Biopharmaceuticals Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-35.4B
KRW
Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Income from Continuing Operations amounts to -35.4B KRW.
What is SK Biopharmaceuticals Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
24%
Over the last year, the Income from Continuing Operations growth was 75%. The average annual Income from Continuing Operations growth rates for SK Biopharmaceuticals Co Ltd have been 48% over the past three years , 24% over the past five years .
You don't have any saved screeners yet
